KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash & Current Investments (2017 - 2026)

Aquestive Therapeutics has reported Cash & Current Investments over the past 9 years, most recently at $121.2 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 69.36% year-over-year to $121.2 million; the TTM value through Dec 2025 reached $121.2 million, up 69.36%, while the annual FY2025 figure was $121.2 million, 69.36% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $121.2 million at Aquestive Therapeutics, down from $129.1 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $129.1 million in Q3 2025 and troughed at $14.7 million in Q1 2022.
  • A 5-year average of $50.6 million and a median of $29.6 million in 2021 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: crashed 48.31% in 2022 and later soared 300.56% in 2024.
  • Year by year, Cash & Current Investments stood at $28.0 million in 2021, then dropped by 2.68% to $27.3 million in 2022, then fell by 12.47% to $23.9 million in 2023, then skyrocketed by 199.71% to $71.5 million in 2024, then skyrocketed by 69.36% to $121.2 million in 2025.
  • Business Quant data shows Cash & Current Investments for AQST at $121.2 million in Q4 2025, $129.1 million in Q3 2025, and $60.5 million in Q2 2025.